<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03893370</url>
  </required_header>
  <id_info>
    <org_study_id>016</org_study_id>
    <nct_id>NCT03893370</nct_id>
  </id_info>
  <brief_title>RejuvenAir® System Trial for COPD With Chronic Bronchitis</brief_title>
  <acronym>SPRAY-CB</acronym>
  <official_title>A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease With Chronic Bronchitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSA Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSA Medical, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air&#xD;
      within the lungs and is a major public health problem that is projected to rank fifth&#xD;
      worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis (CB)&#xD;
      is a common clinical phenotype within the umbrella of a COPD diagnosis and is classically&#xD;
      defined as chronic cough and sputum production for 3 months a year for 2 consecutive years2,&#xD;
      but many studies have used different definitions to define it- chronic cough and sputum&#xD;
      production for one year or cough and sputum production on most days of the week. CB is&#xD;
      associated with multiple clinical consequences, including; the worsening of lung function&#xD;
      decline, increasing risk of acute exacerbations of COPD, increased risk of developing&#xD;
      pneumonia, reduced health related quality of life, and an increase in all-cause mortality.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The RejuvenAir® System is a cryosurgical device that applies medical-grade liquid nitrogen to&#xD;
      the treatment area via a radial head catheter in a small, accurately directed spray.&#xD;
      Cryotherapy with the RejuvenAir® System is designed to induce a regenerative endobronchial&#xD;
      tissue effect by: 1) destroying via cryotherapy the abnormal surface epithelium that has&#xD;
      become overgrown with mucin producing goblet cells, 2) thus allowing normal bronchial&#xD;
      epithelium with a regrowth of ciliated epithelial cells that will facilitate the removal of&#xD;
      mucins from the bronchial airways and 3) lead to a reduction in chronic inflammation and its&#xD;
      accompanying mucosal swelling with resultant increase in the treated airway diameter. This&#xD;
      reversal of inflamed epithelium may also lessen systemic inflammation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2020</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>randomized, sham-controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>St. George's Respiratory Questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Change in St. George Respiratory Questionnaire (SGRQ) score from Baseline to 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects experiencing serious adverse events (SAEs) rated as probably or definitely related to the study device or procedure</measure>
    <time_frame>Within 30 days after either the first or second study procedure</time_frame>
    <description>Number of subjects experiencing one or more serious adverse events (SAEs) rated as probably or definitely related to the study device or procedure by the investigator within 30 days after either the first or second study procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of cough</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Reduction of cough from Baseline through 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of sputum</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Reduction of sputum from Baseline through 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Exacerbation Rate (AECOPD)</measure>
    <time_frame>12 months</time_frame>
    <description>Acute Exacerbation rate (AECOPD, all severities) over 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD assessment test (CAT) score</measure>
    <time_frame>12 months</time_frame>
    <description>COPD assessment test (CAT) from Baseline through 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Chronic Bronchitis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RJA MCS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RejuvenAir System</intervention_name>
    <description>RejuvenAir Metered CryoSpray</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Control Procedure</intervention_name>
    <description>Sham Control Procedure</description>
    <arm_group_label>Sham Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Males and females ≥40 to ≤80 years of age&#xD;
&#xD;
          -  Subject is able to read, understand, and sign a written Informed Consent in order to&#xD;
             participate in the Study&#xD;
&#xD;
          -  Subject has a diagnosis of chronic bronchitis (CB) and/or chronic obstructive&#xD;
             pulmonary disease (COPD) for a minimum of two years. (Chronic Bronchitis is defined&#xD;
             clinically as chronic productive cough for 3 months in each of 2 successive years in a&#xD;
             patient in whom other causes of productive cough have been excluded)&#xD;
&#xD;
          -  Subject is classified as having a moderate or severe (GOLD 2/3) airflow obstruction&#xD;
             defined by a post-bronchodilator of ≥30% FEV1 to &lt;80% predicted with a baseline&#xD;
             FEV1/FVC of &lt;0.70&#xD;
&#xD;
          -  Subject has a Baseline SGRQ of ≥50&#xD;
&#xD;
          -  Subject demonstrates daily cough and significant mucus.&#xD;
&#xD;
          -  Subject is being treated according to current medically accepted treatment guidelines&#xD;
             for chronic bronchitis for minimum of 3 months prior to enrollment into the study.&#xD;
             Subject agrees to continue maintenance pulmonary/COPD medications (GOLD standard&#xD;
             medications recommended) for the duration of the study&#xD;
&#xD;
          -  Non-smoking for a minimum of 2 months prior to consent and agrees to continue not&#xD;
             smoking for the duration of the study&#xD;
&#xD;
          -  Subject is able to adhere to and undergo 2 bronchoscopic procedures (cross over&#xD;
             subjects may undergo two additional bronchoscopic procedures, if they agree to&#xD;
             treatment), per hospital guidelines&#xD;
&#xD;
          -  Subject demonstrates ability and willingness to use a daily eDiary&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Subject has had an acute pulmonary infection, exacerbation or pneumonia requiring&#xD;
             medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially&#xD;
             planned study bronchoscopy&#xD;
&#xD;
          -  Current diagnosis of Asthma&#xD;
&#xD;
          -  Subject has Alpha-1 antitrypsin deficiency as defined by blood level &lt;59 mg/dL&#xD;
&#xD;
          -  Subject has other origins of respiratory disease aside from chronic bronchitis and&#xD;
             COPD&#xD;
&#xD;
          -  Subject is using e-cigarettes, vaping or taking any inhaled substances not prescribed&#xD;
             by a physician&#xD;
&#xD;
          -  Subject has untreatable or life threatening arrhythmias, inability to adequately&#xD;
             oxygenate during the bronchoscopy, or has acute respiratory failure&#xD;
&#xD;
          -  Subject has bullous emphysema characterized as large bullae &gt;30 millimeters on HRCT;&#xD;
             or subject has stenosis in the tracheobronchial system, tracheobronchomegaly,&#xD;
             trachea-bronchomalacia, amyloidosis or cystic fibrosis&#xD;
&#xD;
          -  Subject has clinically significant bronchiectasis&#xD;
&#xD;
          -  Subject has had a solid transplant procedure&#xD;
&#xD;
          -  Subject has a known mucosal tear, has undergone prior lung surgery such as&#xD;
             pneumonectomy, lobectomy, bullectomy, or lung volume reduction surgery&#xD;
&#xD;
          -  Subject has had a prior lung device procedure, including emphysema stent(s) implanted,&#xD;
             lung coils, valves, lung denervation, bronchial thermoplasty, cryotherapy or other&#xD;
             therapies&#xD;
&#xD;
          -  Subject is unable to temporarily discontinue use of anticoagulant therapy: warfarin,&#xD;
             Coumadin, LMWH, heparin, clopidrogel (or equal)&#xD;
&#xD;
          -  Subject has a serious medical condition, such as: uncontrolled coagulopathy or&#xD;
             bleeding disorder, congestive heart failure, uncontrolled angina, myocardial&#xD;
             infarction in the past year, renal failure, liver disease, cerebrovascular accident&#xD;
             within the past 6 months, uncontrolled diabetes, uncontrolled hypertension or&#xD;
             uncontrolled gastric reflux&#xD;
&#xD;
          -  Subject is pregnant, nursing, or planning to get pregnant during study duration&#xD;
&#xD;
          -  Subject has or is receiving chemotherapy or active radiation therapy within the past 6&#xD;
             months or is expected to receive chemotherapy during participation in this study&#xD;
&#xD;
          -  Subject is or has been in another treatment study within 6 weeks of enrollment and&#xD;
             agrees to not participate in any other treatment studies for the duration of study&#xD;
             participation&#xD;
&#xD;
          -  Subject has known sensitivity to medication required to perform bronchoscopy (such as&#xD;
             lidocaine, atropine, and benzodiazepines)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerard Criner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Temple University Health System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fran Avery, BS</last_name>
    <phone>781-538-4735</phone>
    <email>fkuhnen@csamedical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joyce Musacchio, BS</last_name>
    <phone>781-538-4794</phone>
    <email>jmusacchio@csamedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Ng</last_name>
      <phone>650-962-4563</phone>
      <email>Karen_Ng@elcaminohospital.org</email>
    </contact>
    <contact_backup>
      <last_name>Janet Lamm</last_name>
      <phone>650-962-4466</phone>
      <email>Janet_Lamm@elcaminohealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Ganesh Krishna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Tham</last_name>
      <phone>916-734-3351</phone>
      <email>ttham@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Ken Yoneda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Pulmonary Research Institute</name>
      <address>
        <city>Loxahatchee Groves</city>
        <state>Florida</state>
        <zip>33470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isis Recarey, RN</last_name>
      <phone>561-795-1022</phone>
      <email>aprirnir@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Liudmila Moreiras, APRN</last_name>
      <phone>561-795-1022</phone>
      <email>aprinpmila@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Neal Warshoff, D.O</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarasota Memorial Hospital</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angele Price, BSN, RN</last_name>
      <phone>941-917-3614</phone>
      <email>Angele-Price@smh.com</email>
    </contact>
    <contact_backup>
      <last_name>Tamela Fonseca, MSN, RN</last_name>
      <phone>941-917-2475</phone>
      <email>Tamela-Fonseca@smh.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joseph C. Seaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Pulmonary Specialists</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Medical Center</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Misty Prince</last_name>
      <phone>318-813-1456</phone>
      <phone_ext>214</phone_ext>
      <email>Misty.Prince@lsuhs.edu</email>
    </contact>
    <contact_backup>
      <last_name>Norma Phillips</last_name>
      <email>norma.phillips@lsuhs.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Holladay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Universtiy</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Conley</last_name>
      <phone>617-632-8386</phone>
      <email>cconley@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Adnan Majiid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Day, RN, BSN</last_name>
      <phone>313-916-1254</phone>
      <email>jday5@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Michael Simoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Health</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona L Wojtas</last_name>
      <phone>616-486-2054</phone>
      <email>JMona.Wojtas@spectrumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Gustavo Cumbo-Nacheli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aboubacar Cherif</last_name>
      <phone>603-650-0567</phone>
      <email>Aboubacar.Cherif@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>David Feller-Kopman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cooper Health System</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Grant</last_name>
      <phone>856-968-7366</phone>
      <email>grant-katie@cooperhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christine Rickette</last_name>
      <phone>856-342-3024</phone>
      <email>rickette-chris@cooperhealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wissam Abouzgheib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Coles</last_name>
      <phone>919-668-3812</phone>
      <email>kathleen.coles@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Shier</last_name>
      <phone>919-684-9139</phone>
      <email>Jessica.shier@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Momen Wahidi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane M Faile</last_name>
      <phone>216-445-7599</phone>
      <email>failed@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne M Meli</last_name>
      <phone>216-445-4215</phone>
      <email>meliy@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Gildea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State Universisty</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamaal Saleh, BS</last_name>
      <phone>614-366-2258</phone>
      <email>jamaal.saleh@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Ghattas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple University - Of the Commonwealth System of Higher Education</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CR Department</last_name>
      <phone>215-707-1359</phone>
      <email>breathe@temple.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Criner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Blanton</last_name>
      <phone>843-792-8438</phone>
      <email>blantonm@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Charlton Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health - Midlands</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Henson</last_name>
      <phone>803-434-3685</phone>
      <email>melissa.henson@prismahealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Sholts</last_name>
      <phone>803-434-8262</phone>
      <email>jennifer.sholts@prismahealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>William Tillis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhoda Annoh Gordon</last_name>
      <phone>214-645-6493</phone>
      <email>adetoun.sodimu@UTSouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Muhanned Abu-Hijleh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Gilles, BS, CCRC</last_name>
      <phone>608-265-8057</phone>
      <email>mpgilles@clinicaltrials.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>J S Ferguson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 28, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

